QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NASDAQ:DVAX

Dynavax Technologies - DVAX Stock Forecast, Price & News

$9.96
+0.09 (+0.91%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.79
$10.05
50-Day Range
$9.44
$11.88
52-Week Range
$7.26
$17.48
Volume
1.21 million shs
Average Volume
1.54 million shs
Market Capitalization
$1.27 billion
P/E Ratio
5.06
Dividend Yield
N/A
Price Target
$24.33

Dynavax Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
144.3% Upside
$24.33 Price Target
Short Interest
Bearish
12.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$232,211 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.50) to ($0.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

126th out of 983 stocks

Pharmaceutical Preparations Industry

45th out of 478 stocks


DVAX stock logo

About Dynavax Technologies (NASDAQ:DVAX) Stock

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Here Are 3 Healthcare Stocks That Deliver
Q4 2022 Dynavax Technologies Corp Earnings Call
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
DVAX.OQ - | Stock Price & Latest News | Reuters
Dynavax Stock Gaps Down On Today's Open (DVAX)
I'm Going to Give This Biotech Another Shot
Dynavax to Present at Two Upcoming Investor Conferences
See More Headlines
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Company Calendar

Last Earnings
11/04/2021
Today
3/21/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
311
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+144.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$293.16 million
Pretax Margin
40.72%

Debt

Sales & Book Value

Annual Sales
$722.68 million
Cash Flow
$2.45 per share
Book Value
$4.55 per share

Miscellaneous

Free Float
115,799,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
1.45

Social Links


Key Executives

  • Ryan SpencerRyan Spencer
    Chief Executive Officer & Director
  • David F. NovackDavid F. Novack
    President & Chief Operating Officer
  • Kelly MacDonaldKelly MacDonald
    Chief Financial Officer & Senior Vice President
  • Robert JanssenRobert Janssen
    Chief Medical Officer & SVP-Clinical Development
  • Todd Lopeman
    Vice President-Technical Operations













DVAX Stock - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price forecast for 2023?

3 analysts have issued 1 year price objectives for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $27.00. On average, they predict the company's stock price to reach $24.33 in the next year. This suggests a possible upside of 144.3% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2023?

Dynavax Technologies' stock was trading at $10.64 at the beginning of the year. Since then, DVAX stock has decreased by 6.4% and is now trading at $9.96.
View the best growth stocks for 2023 here
.

Are investors shorting Dynavax Technologies?

Dynavax Technologies saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 16,160,000 shares, a decrease of 13.3% from the February 13th total of 18,640,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is currently 10.0 days.
View Dynavax Technologies' Short Interest
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company had revenue of $108.27 million for the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 65.26% and a net margin of 40.56%. During the same quarter in the previous year, the business earned ($0.15) EPS.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.59%), Fisher Asset Management LLC (3.20%), Blair William & Co. IL (1.95%), Geode Capital Management LLC (1.74%), Morgan Stanley (1.60%) and Dimensional Fund Advisors LP (1.40%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends
.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $9.96.

How much money does Dynavax Technologies make?

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.27 billion and generates $722.68 million in revenue each year. The biopharmaceutical company earns $293.16 million in net income (profit) each year or $1.97 on an earnings per share basis.

How many employees does Dynavax Technologies have?

The company employs 311 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.

This page (NASDAQ:DVAX) was last updated on 3/21/2023 by MarketBeat.com Staff